organization · Reporting owner
White Winston Select Asset Fund Series Fund MP-18, LLC
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MusclePharm CorpMSLP · Entity 125097 | 10% owner | March 29, 2022 | March 31, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MusclePharm Corp
Report date March 29, 2022 · Filed March 31, 2022
Jointly reported with White Winston Select Asset Funds, LLC, Enright Todd M., BLUNDELL MARK, Feagan Donald, Mahoney Robert P
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,021,529 |
Reported balance
After 2022-03-29 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2022-03-29 · Sale · Disposed 626,826 · Balance 3,021,529 F1: On March 29, 2022 (the "Transaction Date"), the Reporting Persons transferred 626,826 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), in an off-market transaction (the "Transaction"). F2: For purposes of the Transaction, the value of the transferred shares of Common Stock was deemed to be $0.39 per share, the last reported sale price of the Issuer's Common Stock on the Transaction Date. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 29, 2022 (the "Transaction Date"), the Reporting Persons transferred 626,826 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), in an off-market transaction (the "Transaction").
F2: For purposes of the Transaction, the value of the transferred shares of Common Stock was deemed to be $0.39 per share, the last reported sale price of the Issuer's Common Stock on the Transaction Date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 29, 2022 Filed Mar 31, 2022 19:19 UTC | MusclePharm Corp MSLP · Entity 125097 | SaleCommon Stock | 626,826 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-012980 · doc4.xml · nonDerivative · entry 1 White Winston Select Asset Fund Series Fund MP-18, LLC · CIK 0001738154 · 10% owner White Winston Select Asset Funds, LLC · CIK 0001647840 · 10% owner Enright Todd M. · CIK 0001647702 · 10% owner BLUNDELL MARK · CIK 0001008190 · 10% owner Feagan Donald · CIK 0001647837 · 10% owner Mahoney Robert P · CIK 0001559652 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,021,529 F1 · kind: On March 29, 2022 (the "Transaction Date"), the Reporting Persons transferred 626,826 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), in an off-market transaction (the "Transaction"). F2 · price: For purposes of the Transaction, the value of the transferred shares of Common Stock was deemed to be $0.39 per share, the last reported sale price of the Issuer's Common Stock on the Transaction Date. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 21:36 UTC | MusclePharm Corp MSLP · Entity 125097 | PurchaseCommon Stock | 626,826 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-024825 · doc4.xml · nonDerivative · entry 1 White Winston Select Asset Fund Series Fund MP-18, LLC · CIK 0001738154 · 10% owner White Winston Select Asset Funds, LLC · CIK 0001647840 · 10% owner Enright Todd M. · CIK 0001647702 · 10% owner BLUNDELL MARK · CIK 0001008190 · 10% owner Feagan Donald · CIK 0001647837 · 10% owner Mahoney Robert P · CIK 0001559652 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,658,180 F1 · kind: On September 30, 2019, the Reporting Person purchased 626,826 shares of Common Stock, par value $0.001 per share, of the issuer ("Common Stock") in an off-market transaction. F2 · price: For purposes of the transaction, the value of the Common Stock was deemed to be $0.45 per share, the last reported sale price of the Common Stock on the Transaction Date. Read SEC document |
| September 30, 2019 Filed Nov 8, 2019 12:26 UTC Amendment | MusclePharm Corp MSLP · Entity 125097 | PurchaseCommon Stock | 626,826 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-026927 · doc4a.xml · nonDerivative · entry 1 White Winston Select Asset Fund Series Fund MP-18, LLC · CIK 0001738154 · 10% owner White Winston Select Asset Funds, LLC · CIK 0001647840 · 10% owner Enright Todd M. · CIK 0001647702 · 10% owner BLUNDELL MARK · CIK 0001008190 · 10% owner Feagan Donald · CIK 0001647837 · 10% owner Mahoney Robert P · CIK 0001559652 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,648,355 F1 · balance_after: This Form 4 amends a Form 4 filed by the reporting person on October 2, 2019, which erroneously reported in Table I, Column 5 that the amount of securities beneficially owned following the reported transaction was 3,658,180, rather than 3,648,355. Read SEC document |
| September 27, 2019 Filed Oct 1, 2019 20:18 UTC | MusclePharm Corp MSLP · Entity 125097 | PurchaseCommon Stock | 103,677 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-024534 · doc4.xml · nonDerivative · entry 1 White Winston Select Asset Fund Series Fund MP-18, LLC · CIK 0001738154 · 10% owner White Winston Select Asset Funds, LLC · CIK 0001647840 · 10% owner Enright Todd M. · CIK 0001647702 · 10% owner BLUNDELL MARK · CIK 0001008190 · 10% owner Feagan Donald · CIK 0001647837 · 10% owner Mahoney Robert P · CIK 0001559652 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,031,354 F1 · kind: On September 27, 2019, 103,677 shares of Common Stock, par value $0.001 per share, of the issuer ("Common Stock") were acquired by the reporting person in consideration for membership interests in the reporting person. F2 · price: The Common Stock was valued at $1.00 per share for the purpose of determining the amount of membership interest issued. Read SEC document |
| September 27, 2019 Filed Nov 8, 2019 12:18 UTC Amendment | MusclePharm Corp MSLP · Entity 125097 | PurchaseCommon Stock | 93,852 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-026925 · doc4a.xml · nonDerivative · entry 1 White Winston Select Asset Fund Series Fund MP-18, LLC · CIK 0001738154 · 10% owner White Winston Select Asset Funds, LLC · CIK 0001647840 · 10% owner Enright Todd M. · CIK 0001647702 · 10% owner BLUNDELL MARK · CIK 0001008190 · 10% owner Feagan Donald · CIK 0001647837 · 10% owner Mahoney Robert P · CIK 0001559652 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,021,529 F1 · shares: This Form 4 amends a Form 4 filed by the reporting person on October 1, 2019, which erroneously reported in (i) Table I, Column 4 that the number of securities acquired in the reported transaction was 103,677, rather than 93,852 and (ii) Table I, Column 5 that the amount of securities beneficially owned following the reported transaction was 3,031,354, rather than 3,021,529. F1 · balance_after: This Form 4 amends a Form 4 filed by the reporting person on October 1, 2019, which erroneously reported in (i) Table I, Column 4 that the number of securities acquired in the reported transaction was 103,677, rather than 93,852 and (ii) Table I, Column 5 that the amount of securities beneficially owned following the reported transaction was 3,031,354, rather than 3,021,529. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.